Experienced in Gliosarcoma

Dr. John F. Deeken

Oncology | Hematology Oncology
Inova Health Care Services
8081 Innovation Park Dr, 
Fairfax, VA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Gliosarcoma
Inova Health Care Services
8081 Innovation Park Dr, 
Fairfax, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Deeken is an Oncologist and a Hematologist Oncology provider in Fairfax, Virginia. Dr. Deeken is rated as an Experienced provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Laryngeal Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, and Oral Squamous Cell Carcinoma. Dr. Deeken is currently accepting new patients.

His clinical research consists of co-authoring 47 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in DC
Hospital Affiliations
Inova Fairfax Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthKeepers
  • POS
Innovation Health
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

INOVA HEALTH CARE SERVICES
8081 Innovation Park Dr, Fairfax, VA 22031

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: January 26, 2026
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Peposertib
Study Phase: Phase 1
A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
Study Drug: Enzalutamide
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Suspended
Publish Date: January 14, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2/Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Cisplatin, Carboplatin
Study Phase: Phase 2
Safety Evaluations of Nivolumab (Anti-PD-1) Added To Chemotherapy (CRT) Platforms In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Safety Evaluations of Nivolumab (Anti-PD-1) Added To Chemotherapy (CRT) Platforms In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: November 29, 2022
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Cisplatin, Cetuximab
Study Phase: Phase 1
View 8 Less Clinical Trials

46 Total Publications

Larotrectinib-associated withdrawal symptoms resolved following initiation of GLP-1 receptor agonist: a case report.
Larotrectinib-associated withdrawal symptoms resolved following initiation of GLP-1 receptor agonist: a case report.
Journal: Cancer chemotherapy and pharmacology
Published: August 21, 2025
Similar Doctors
Distinguished in Gliosarcoma
Dr. Daya S. Sharma
Oncology | Hematology Oncology | Hematology
Distinguished in Gliosarcoma
Dr. Daya S. Sharma
Oncology | Hematology Oncology | Hematology

American Oncology Partners PA

106 Irving St Nw, Suite 4100, 
Washington, DC 
 (12.4 miles away)
202-726-0941
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients

Daya Sharma is an Oncologist and a Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Sharma is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Astrocytoma, Gliosarcoma, Embryonal Tumor with Multilayered Rosettes, and Neuroepithelioma. Dr. Sharma is currently accepting new patients.

David O. Kamson
Distinguished in Gliosarcoma
Dr. David O. Kamson
Oncology
Distinguished in Gliosarcoma
Dr. David O. Kamson
Oncology

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
 (44.3 miles away)
410-955-8964
Languages Spoken:
English, Hungarian
See accepted insurances
Offers Telehealth

David Kamson is an Oncologist in Baltimore, Maryland. Dr. Kamson is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Brain Tumor, Glioblastoma, Gliosarcoma, Metastatic Brain Tumor, and Hormone Replacement Therapy (HRT).

Advanced in Gliosarcoma
Dr. Behzad Doratotaj
Hematology Oncology | Hematology | Oncology
Advanced in Gliosarcoma
Dr. Behzad Doratotaj
Hematology Oncology | Hematology | Oncology

Medstar Medical Group Ii LLC

18105 Prince Philip Dr, 
Olney, MD 
 (22.1 miles away)
301-774-8962
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Behzad Doratotaj is a Hematologist Oncology specialist and a Hematologist in Olney, Maryland. Dr. Doratotaj is rated as an Advanced provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Oligodendroglioma, Astrocytoma, Embryonal Tumor with Multilayered Rosettes, and Glioblastoma. Dr. Doratotaj is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Deeken's expertise for a condition
ConditionClose
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile